The Cooper Companies, Inc. (NASDAQ:COO) Stock Has Consensus Target Price of $68.60 According to Brokerages

Shares of The Cooper Companies, Inc. (NASDAQ:COO) have been assigned a consensus recommendation of “Hold” from the nineteen analysts that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $68.60.

COO has been the topic of a number of recent research reports. Bank of America reaffirmed a “neutral” rating and issued a $65.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. UBS Group decreased their price objective on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a research note on Thursday, September 10th. Piper Sandler reiterated a “neutral” rating on shares of Cooper Companies in a research report on Thursday, October 15th. Barclays upgraded Cooper Companies to a “hold” rating in a research report on Wednesday, October 7th. Finally, Mizuho set a $75.00 target price on shares of Cooper Companies and gave the company an “outperform” rating in a research note on Thursday, September 10th.

Insiders Place Their Bets

In other Cooper Companies news, Director Paul A. Keel bought 4,701 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was purchased at an average cost of $53.18 per share, for a total transaction of $249,999.18. Following the completion of the purchase, the director owned 4,701 shares of the company’s stock, valued at $249,999.18. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lawrence Kurzius bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average price of $53.91 per share, with a total value of $539,100.00. Following the completion of the purchase, the director directly owned 21,099 shares of the company’s stock, valued at approximately $1,137,447.09. The trade was a 90.10% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 34,701 shares of company stock valued at $1,880,039 in the last quarter. 2.08% of the stock is currently owned by company insiders.

Institutional Trading of Cooper Companies

A number of hedge funds have recently added to or reduced their stakes in COO. BlackRock Inc. acquired a new position in shares of Cooper Companies during the 2nd quarter valued at about $1,077,762,000. Generation Investment Management LLP purchased a new position in Cooper Companies during the second quarter worth approximately $356,304,000. Jupiter Topco LLC purchased a new position in Cooper Companies during the second quarter worth approximately $305,074,000. JANA Partners Management LP raised its stake in Cooper Companies by 0.5% during the second quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company’s stock worth $256,900,000 after purchasing an additional 17,322 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of Cooper Companies by 3.1% in the 2nd quarter. Wellington Management Group LLP now owns 3,468,951 shares of the medical device company’s stock valued at $248,758,000 after purchasing an additional 103,044 shares during the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Stock Performance

NASDAQ:COO opened at $59.88 on Wednesday. The firm has a 50-day moving average price of $61.31 and a two-hundred day moving average price of $69.45. Cooper Companies has a twelve month low of $51.01 and a twelve month high of $89.83.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the company earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts anticipate that Cooper Companies will post 4.53 earnings per share for the current year.

Cooper Companies declared that its Board of Directors has authorized a stock buyback plan on Wednesday, September 9th that allows the company to repurchase $3 billion in shares. This repurchase authorization allows the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reaffirmed its fiscal 2026 guidance, signaling that management does not currently expect the leadership transition to alter its financial outlook. The company also appointed healthcare veteran Walt Rosebrough as executive chair; his experience leading medical-device businesses could support operational improvements and shareholder-value initiatives. CooperCompanies Announces Leadership Transition and Board Refreshment
• Positive Sentiment: The planned addition of former Johnson & Johnson medical-device executive Shlomi Nachman and the nomination of a smaller, refreshed seven-member board may improve governance, oversight and strategic execution. CooperCompanies Elects Walt Rosebrough Executive Chair, Announces CEO Search and Board Refreshment
• Neutral Sentiment: Rosebrough is overseeing day-to-day operations while the company searches for a permanent CEO. Outgoing CEO Al White will remain as a strategic adviser through April 2027, which may provide some transition continuity.
• Negative Sentiment: White’s immediate departure as president, CEO and director increases leadership risk. Rosebrough acknowledged that recent performance has fallen short of expectations, potentially reinforcing concerns about the company’s operating momentum and strategy. Cooper Companies CEO White Steps Down
• Negative Sentiment: Rosen Law Firm announced an investigation into potential securities claims alleging that CooperCompanies may have issued materially misleading business information. The announcement does not establish wrongdoing, but it adds legal and reputational risk and may weigh on investor sentiment. Rosen Law Firm Securities Class Action Investigation

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.